Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Resistance to darunavir].

Enfermedades infecciosas y microbiologia clinica - 1 Oct 2008

García Deltoro Miguel

Abstract excerpt

The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604). The two strongest predictors of virological response were firstly baseline phenotype expressed as the darunavir fold change in 50% effective concentration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Clinical Trials, Phase III as Topic
Share to Darunavir

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lopinavir

Share to Multicenter Studies as Topic

Share to Nitriles

Share to Pyridazines

Share to Pyrimidinones

Source

Identifiers

PMID: 19195460
DOI: 10.1016/s0213-005x(08)76554-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Resistance to darunavir].PMID 19195460Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.Semantic proximity Read ↗

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.Semantic proximity Read ↗

[Resistance to nucleoside reverse transcriptase inhibitors].Semantic proximity Read ↗

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.Semantic proximity Read ↗

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.Semantic proximity Read ↗

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.Semantic proximity Read ↗

[Resistance to non-nucleoside reverse transcriptase inhibitors].Semantic proximity Read ↗

[Resistance to antiretroviral agents: mechanism and study methods].Semantic proximity Read ↗

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.Semantic proximity Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

[Etravirine: genetic barrier and resistance development].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.